B-type Natriuretic Peptide (BNP) Testing

BNP (or NT-proBNP) testing is covered when used with clinical assessment to distinguish cardiac causes of acute dyspnea, to differentiate decompensated CHF from COPD exacerbation in symptomatic comorbid patients, and for risk stratification in acute coronary syndrome when obtained within the first few days of symptom onset. BNP testing as screening in asymptomatic patients (e.g., as part of cardiovascular risk panels) and BNP testing for routine monitoring or to guide therapy in chronic heart failure are not covered; results must be interpreted alongside standard diagnostic studies and clinical findings.

"Measurement of BNP is covered to help distinguish cardiac causes of acute dyspnea from pulmonary or other non-cardiac causes when used with clinical assessment and standard diagnostic tests."

Sign up to see full coverage criteria, indications, and limitations.